Table 2.
Antibiotic susceptibility testing results
| Antimicrobial class | Antibiotic | Resistant No (%) | Intermediate No (%) | Susceptible No (%) |
|---|---|---|---|---|
| Aminoglycosides | Gentamicin | 106 (96.36%) | 0 (0%) | 4 (3.63%) |
| Amikacin | 100 (90.9%) | 5 (4.54%) | 5 (4.54%) | |
| Tobramycin | 110 (100%) | 0 (0%) | 0 (0%) | |
| Folate pathway inhibitors | Trimethoprim-sulfamethoxazole | 110 (100%) | 0 (0%) | 0 (0%) |
| Carbapenems | Imipenem | 108 (98.18%) | 2 (1.81%) | 0(0%) |
| Meropenem | 110(100%) | 0 (0%) | 0 (0%) | |
| Cephems | Cefotaxime | 110 (100%) | 0 (0%) | 0 (0%) |
| Ceftriaxone | 110 (100%) | 0 (0%) | 0(0%) | |
| Cefepime | 110(100%) | 0 (0%) | 0 (0%) | |
| Ceftazidime | 110 (100%) | 0 (0%) | 0 (0%) | |
| Fluoroquinolones | Ciprofloxacin | 110 (100%) | 0 (0%) | 0(0%) |
| Tetracyclines | Tetracycline | 95 (86.36%) | 12 (10.9%) | 3(2.72%) |
| β-lactam/β-lactamase inhibitor combinations | Piperacillin/Tazobactam | 110 (100%) | 0 (0%) | 0 (0%) |
| Penicillins | Piperacillin | 110 (100%) | 0 (0%) | 0(0%) |